RecruitingNot ApplicableNCT05422859

Mobile and Digital Application in Heart Failure Networks Berlin/Brandenburg


Sponsor

German Heart Institute

Enrollment

50 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The MobiDig trial is designed to evaluate an implementation of a mobile phone application with secondary preventive/rehabilitative modules for patients with heart failure in certified Heart Failure Unit centers in Berlin and Brandenburg. The aim is to evaluate the effect on quality of life, symptoms and the course of the disease. In addition, the acceptance, adherence and user behavior as well as the implementation potential for a permanent introduction of the application in national heart failure networks will be analyzed.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Confirmed diagnosis of heart failure
  • Treatment in a certified Heart Failure Unit center in Berlin or Brandenburg
  • Written informed consent of the participants
  • User of a mobile device with an iOS operating system

Exclusion Criteria2

  • Addiction or other illnesses that do not allow the participants to assess the nature and scope as well as possible consequences of participation or its scientific evaluation
  • insufficient knowledge of the German language, which is necessary to use the application

Interventions

OTHERMobiDig

The application will contain the following modules: 1. information and knowledge about heart failure; 2. vital sign diary, which can be sent to the certified HFU 3. pedometer (individualized step-goal), cardiac home training videos 4. "frequently asked questions" and connection to a certified HFU provider by a heart failure hotline


Locations(3)

Deutsches Herzzentrum der Charité - Universitätsmedizin Berlin

Berlin, Deutschland, Germany

Charité - Universitätsmedizin Berlin: Campus Virchow-Klinikum

Berlin, Germany

Herzzentrum Berlin

Bernau, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05422859


Related Trials